Renoprotection in diabetes: Genetic and non-genetic risk factors and treatment

Diabetologia

Volumn 41, Issue 7, 1998, Pages 745-759

  Parving, H H ^a  

^a STENO DIABETES CENTER   (Denmark)

Author keywords

Angiotensin converting inhibition; Antihypertensive treatment; Diabetic nephropathy; End stage renal failure; Glycaemic control; Insertion deletion polymorphism of angiotensin converting enzyme gene; Microalbuminuria; Renal progression promoters; Type I and Type II diabetes

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ANTIHYPERTENSIVE THERAPY; CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDICATION; GENETIC RISK; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN INTAKE; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CAPTOPRIL; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; RISK FACTORS;

EID: 0031863754     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250050983     Document Type: Review

References (191)

1. Parving H-H, Andersen AR, Smidt UM, Svendsen PA (1983) Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet I:1175-1179
2. Parving H-H, Gall M-A, Skøtt P et al. (1992) Prevalence and causes of albuminuria in non-insulin-dependent diabetic patients. Kidney Int 41: 758-762
3. Parving H-H, Østerby R, Anderson PW, Hsueh WA (1996) Diabetic nephropathy. In: Brenner BM (ed) The Kidney, 5th edn. Saunders, Philadelphia, pp 1864-1892
4. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T (1983) Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 25: 496-501
5. Krolewski AS, Warram JH, Christlieb AR, Busick EJ, Kahn CR (1985) The changing natural history of nephropathy in Type 1 diabetes. Am J Med 78: 785-794
6. Kofoed-Enevoldsen A, Borch-Johnsen K, Kreiner S, Nerup J, Deckert T (1987) Declining incidence of persistent proteinuria in type 1 (insulin-dependent) diabetic patients in Denmark. Diabetes 36: 205-209
7. Rossing P, Rossing K, Jacobsen P, Parving H-H (1995) Unchanged incidence of diabetic nephropathy in IDDM patients. Diabetes 44: 739-743
8. Ballard DJ, Humphrey LL, Melton III LJ et al. (1988) Epidemiology of persistent proteinuria in Type II diabetes mellitus. Population-based study in Rochester, Minnesota. Diabetes 37: 405-412
9. Kunzelman CL, Knowler WC, Pettitt DJ, Bennett PH (1989) Incidence of nephropathy in type 2 diabetes mellitus in the Pima Indians. Kidney Int 35: 681-687
10. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg B, Ludvigsson J (1994) Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 330: 15-18
11. Parving H-H (1997) Strategies to reduce the burden of diabetic complications. Diabetologia 8: 9-10
12. Knowles HCJ (1971) Long term juvenile diabetes treated with unmeasured diet. Trans Assoc Am Physicians 84: 95-101
13. Mogensen CE (1982) Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 285: 685-688
14. Viberti GC, Bilous RW, Mackintosh D, Keen H (1983) Monitoring glomcrular function in diabetic nephropathy. Am J Med 74: 256-264
15. Parving H-H, Smidt UM, Friisberg B, Bonnevie-Nielsen V, Andersen AR (1981) A prospective study of glomerular filtration rate and arterial blood pressure in insulin-dependent diabetics with diabetic nephropathy. Diabetologia 20: 457-461
16. Gall M-A, Nielsen FS, Smidt UM, Parving H-H (1993) The course of kidney function in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy. Diabetologia 36: 1071-1078
17. Biesenbach G, Janko O, Zazgornik J (1994) Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol Dial Transplant 9: 1097-1102
18. Ritz E, Stefanski A (1996) Diabetic nephropathy in type II diabetes. Am J Kidney Dis 27: 167-194
19. Parving H-H, Andersen AR, Smidt UM, Oxenbøll B, Edsberg B, Christiansen JS (1983) Diabetic nephropathy and arterial hypertension. Diabetologia 24: 10-12
20. Parving H-H, Hommel E, Mathiesen ER et al. (1988) Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin-dependent diabetes. BMJ 296: 156-160
21. Tarnow L, Rossing P, Gall M-A. Nielsen FS, Parving H-H (1994) Prevalence of arterial hypertension in diabetic patients before and after the JNC-V. Diabetes Care 17 (11): 1247-1251
22. Rossing P, Hommel E, Smidt UM, Parving H-H (1993) Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 42: 715-719
23. Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FIR (1994) Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 43: 1046-1051
24. Krolewski AS, Warram JH, Christlieb AR (1994) Hypercholesterolemia - A determinant of renal function loss and deaths in IDDM patients with nephropathy. Kidney Int 45 [suppl 45]:S125-S131
25. Breyer JA, Bain P, Evans JK et al. (1996) Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50: 1651-1658
26. Yokoyama H, Tomonaga O, Hirayama M et al. (1997) Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia 40: 405-411
27. Jacobson HR (1991) Chronic renal failure:pathophysiology. Lancet 338: 419-423
28. Hostetter TH, Rennke HG, Brenner BM (1982) The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 72: 375-380
29. Brenner BM (1983) Hemodynamically mediated glomerular injury and the progressive nature of kidney disease. Kidney Int 23: 647-655
30. Jensen PK, Steven K, Blæhr H, Christiansen JS, Parving H-H (1986) The effects of indomethacin on glomerular hemodynamics in experimental diabetes. Kidney Int 29: 490-495
31. Levey AS, Gassman J, Hall PM, Walker WG (1991) Assessing the progression of renal disease in clinical studies:effects of duration of follow-up and regression to the mean. J Am Soc Nephrol 1: 1087-1094
32. Remuzzi G, Bertani T (1990) Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 38: 384-394
33. Watkins PJ, Blainey JD, Brewer DB et al. (1972) The natural history of diabetic renal disease. A follow-up study of series of renal biopsies. QJM 41: 437-456
34. Parving H-H, Rossing P, Hommel E, Smidt UM (1995) Angiotensin converting enzyme inhibition in diabetic nephropathyten years experience. Am J Kidney Dis 26: 99-107
35. Nelson RG, Bennett PH, Beck GJ et al. (1996) Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. N Engl J Med 335: 1636-1642
36. The Gisen Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349: 1857-1863
37. Berglund J, Lins L-E, Lins P-E (1985) Metabolic and blood pressure monitoring in diabetic renal failure. Acta Med Scand 218: 401-408
38. Hasslacher C, Stech W, Wahl P, Ritz E (1985) Blood pressure and metabolic control as risk factors for nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 28: 6-11
39. Nyberg G, Blohmé G, Nordén G (1987) Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30: 82-86
40. Mulec H, Blohmé G, Grände B, Björck S (1995) Progression of overt diabetic nephropathy (DN): role of metabolic control. J Am Soc Nephrol 6: 453(Abstract)
41. Alaveras A, Thomas SM, Sagriotis A, Viberti GC (1997) Promoters of progression of diabetic nephropathy:the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 12: 71-74
42. Wu M, Yu C, Yang C-W et al. (1997) Poor pre-dialysis glycaemic control is a predictor of mortality in type II diabetic patients on maintenance haemodialysis. Nephrol Dial Transplant 12: 2105-2110
43. Porte D, Schwartz M (1996) Diabetes complications:why is glucose potentially toxic? Science 272: 699-700
44. 43b. Ortiz A, Ziyadeh FN, Neilson EG (1997) Expression of Apoptosis-regulatory genes in renal proximal tubular epithelial alls expesed to high arribient glucose and in diabetic kidneys. J Invest Med 45: (2) 50-56
45. Moorhead JF, El-Nahas M, Chan MK, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet ii:1309-1311
46. Hommel E, Andersen P, Gall M-A et al. (1992) Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy. Diabetologia 35: 447-451
47. Lam KS, Cheng IKP, Janus ED, Pang RWC (1995) Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 38: 604-609
48. Nielsen S, Schmitz O, Møller N et al. (1993) Renal function and insulin sensitivity during simvastatin treatment in Type 2 (non-insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 36: 1079-1086
49. Ciavarella A, Di Mizio G, Stefani S, Borgnina LC, Vannini P (1987) Reduced albuminuria after dietary protein restriction in insulin-dependent diabetic patients with clinical nephropathy. Diabetes Care 10: 407-413
50. Zeller KR, Whittaker E, Sullivan L, Raskin P, Jacobson HR (1991) Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes melitus. N Engl J Med 324: 78-84
51. Dullaart PF, Beusekamp BJ, Meijer S, van Doormaal JJ, Sluiter WJ (1993) Long-term effects of protein-restricted diet on albuminuria and renal function in IDDM patients without clinical nephropathy and hypertension. Diabetes Care 16,2:483-492
52. Barsotti G, Ciardella F, Morelli E, Cupisti A, Mantovanelli A, Giovanetti S (1988) Nutritional treatment of renal failure in type 1 diabetic nephropathy. Clin Nephrol 29: 280-287
53. Walker JD, Bending JJ, Dodds RA et al. (1989) Restriction of dietary protein and progression of renal failure in diabetic nephropathy. Lancet ii:1411-1415
54. Pedrini MT, Levey AS, Lau J, Chalmers TC, Wang PH (1996) The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases:meta-analysis. Ann Intern Med 124: 627-632
55. Parving H-H (1997) Effects of dietary protein on renal disease. Ann Intern Med 126: 330-331
56. Christiansen JS (1978) Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus. Diabetes Care 1: 146-149
57. Orth SR, Ritz E, Schrier RW (1997) The renal risk of smoking. Kidney Int 51: 1669-1677
58. Sawicki PT, Didjurgeit U, Mühlhauser I, Bender R, Heinemann L, Berger M (1994) Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17: 126-131
59. Hansen HP, Rossing P, Jacobsen P, Jensen BR, Parving H-H (1996) The acute effect of smoking on systemic haemodynamics, kidney and endothelial function in insulin-dependent diabetic patients with microalbuminuria. Scand J Clin Lab Invest 56: 393-399
60. Hinchliffe SA, Lynch MRJ, Sargent PH, Howard CV, van Velzen D (1992) The effect of intrauterine growth retardation on the development of renal nephrons. British Journal of Obstetrics and Gynaecology 99: 296-301
61. Brenner BM, Chertow GM (1994) Congenital oligonephropathy and the etiology of adult hypertension and progressive renal injury. Am J Kidney Dis 23: 171-175
62. Rossing P, Tarnow L, Nielsen FS, Boelskifte S, Brenner BM, Parving H-H (1995) Short stature and diabetic nephropathy. BMJ 310: 296-297
63. Gould MM, Mohamed-Ali V, Goubet SA, Yudkin JS, Haines AP (1993) Microalbuminuria:associations with height and sex in non-diabetic subjects. BMJ 306: 240-242
64. Rossing P, Tarnow L, Nielsen FS, Hansen BV, Brenner BM, Parving H-H (1995) Low birth weight - a risk factor for development of diabetic nephropathy? Diabetes 44: 1405-1407
65. Jacobsen P, Rossing P, Tarnow L et al. (1996) Low birth weight a progression promoter in diabetic nephropathy ? J Am Soc Nephrol 7: 1359(Abstract)
66. Cambien F, Poirier O, Lecerf L et al. (1992) Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359-60: 641-644
67. Rigat B, Hubert C, Corvol P, Soubrier F (1992) PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP 1) (dipeptidyl-carboxy peptidose 1). Nucleic Acids Res 20
68. Yoshida H, Kuriyama S, Atsumi Y et al. (1996) Angiotensin I converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus. Kidney Int 50: 657-664
69. Schmidt S, Strojek K, Grzeszczak W, Bergis K, Ritz E (1997) Excess of DD homozygotes in haemodialysed patients with type II diabetes. Nephrol Dial Transplant 12: 427-429
70. Schmidt S, Ritz E (1997) Angiotensin I converting enzyme gene polymorphism and diabetic nephropathy in type II diabetes. Nephrol Dial Transplant 12: 37-41
71. Parving H-H, Jacobsen P, Tarnow L et al. (1996) Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme:observational follow up study. BMJ 313: 591-594
72. Marre M, Jeunemaitre X, Gallois Y et al. (1997) Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes. J Clin Invest 99: 1585-1595
73. Björck S, Blohmé G, Sylvén C, Mulec H (1997) Deletion insertion polymorphism of the angiotensin converting enzyme gene and progression of diabetic nephropathy. Nephrol Dial Transplant 12: 67-70
74. Alaveras A, Thomas SM, Margiaglione M et al. (1997) Metabolic and gene predictors of progression of diabetic kidney disease. Diabetologia 40: 64-64
75. Tarnow L, Rossing P, Nielsen FS, Cambien F, Parving H-H (1997) Progression of diabetic nephropathy during long-standing angiotensin converting enzyme (ACE) inhibition - the impact of polymorphisms in the renin angiotensin system. Diabetologia 40:A19(Abstract)
76. Harden PN, Geddes C, Rowe PA et al. (1995) Polymorphisms in angiotensin-converting-enzyme gene and progression of IgA nephropathy. Lancet 345: 1540-1542
77. van Essen GG, Rensma PL, de Zeeuw D et al. (1996) Association between angiotensin-converting-enzyme gene polymorphism and failure of renoprotective therapy. Lancet 347: 94-95
78. Gall M-A, Hougaard P, Borch-Johnsen K, Parving H-H (1997) Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus:prospective, observational study. BMJ 314: 783-788
79. Microalbuminuria Collaborative Study Group UK (1993) Risk factors for development of microalbuminuria in insulin dependent diabetic patients: a cohort study. BMJ 306: 1235-1239
80. Mathiesen ER, Rønn B, Jensen T, Storm B, Deckert T (1990) Relationship between blood pressure and urinary albumin excretion in development of microalbuminuria. Diabetes 39: 245-249
81. Parving H-H, Oxenbøll B, Svendsen PA, Christiansen JS, Andersen AR (1982) Early detection of patients at risk of developing diabetic nephropathy. Acta Endocrinol 100: 550-555
82. Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H (1982) Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet i:1430-1432
83. Mogensen CE, Christensen CK (1984) Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 311:89-93
84. Mathiesen ER, Oxenbøll B, Johansen K, Svendsen PA, Deckert T (1984) Incipient nephropathy in Type 1 (insulin-dependent) diabetes. Diabetologia 26: 406-410
85. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 310: 356-360
86. Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH (1991) Assessing risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 151: 1761-1765
87. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M (1993) Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581
88. Deckert T, Parving H-H, Andersen AR et al. (1982) Diabetic nephropathy. A clinical and morphometric study. In: Eschwege E (ed) Advances in diabetes epidemiology, Elsevier Biomedical Press, Amsterdam, pp 235-243
89. Borch-Johnsen K (1989) The prognosis of insulin-dependent diabetes mellitus. An epidemiological approach. Dan Med Bull 39: 336-349
90. Baldwin DS, Neugarten J (1987) Hypertension and renal diseases. Am J Kidney Dis 10: 186-191
91. Gall M-A, Rossing P, Skøtt P et al. (1991) Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 655-661
92. Borch-Johnsen K, Nørgaard K, Hommel E et al. (1992) Is diabetic nephropathy an inherited complication ? Kidney Int 41: 719-722
93. Seaquist ER, Goetz FC, Rich S, Barbosa J (1989) Familial clustering of diabetic kidney disease: evidence of genetic susceptibility to diabetic nephropathy. N Engl J Med 320: 1161-1165
94. Pettitt DJ, Saad MF, Bennett PH, Nelson RG, Knowler WC (1990) Familial predisposition to renal disease in two generations of Pima Indians with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 33: 438-443
95. Viberti GC, Keen H, Wiseman MJ (1987) Raised arterial pressure in parents of proteinuric insulin-dependent diabetics. BMJ 295: 515-517
96. Walker JD, Tariq T, Viberti GC (1990) Sodium-lithium countertransport activity in red cells of patients with insulin-dependent diabetes and nephropathy and their parents. BMJ 301: 635-638
97. Krolewski AS, Canessa H, Warram JH et al. (1988) Pre-disposition to hypertension and susceptibility to renal disease in insulin-dependent diabetes mellitus. N Engl J Med 318: 140-145
98. Jensen JS, Mathiesen ER, Nørgaard K et al. (1990) Increased blood pressure and erythrocyte sodium-lithium countertransport activity are not inherited in diabetic nephropathy. Diabetologia 33: 619-624
99. Molitch ME, Steffes MW, Cleary PA, Nathan DM (1993) Baseline analysis of renal function in diabetes control and complications trial. Kidney Int 43: 668-674
100. Mangili R, Bending JJ, Scott GS, Lai LK, Gupta A, Viberti GC (1988) Increased sodium-lithium counter transport activity in red cells of patients with insulin dependent diabetes and nephropathy. N Engl J Med 318: 146-150
101. Gall M-A, Rossing P, Jensen JS, Funder J, Parving H-H (1991) Red cell Na/Li countertransport in non-insulin-dependent diabetics with diabetic nephropathy. Kidney Int 39: 135-140
102. Elving LD, Wetzels JFM, de Nobel E, Berden JHM (1991) Erythrocyte sodium-lithium countertransport is not different in type 1 (insulin-dependent) diabetic patients with and without diabetic nephropathy. Diabetologia 34: 126-128
103. Carr S, Mbanya J-C, Thomas T et al. (1990) Increase in glomerular filtration rate in patients with insulin-dependent diabetes and elevated erythrocyte sodium-lithium countertransport. N Engl J Med 322: 500-505
104. Pugh JA (1989) The epidemiology of diabetic nephropathy. Diab Metab Rev 5: 531-546
105. Cowie CC, Port FK, Wolfe RA, Savage PJ, Moll PP, Hawthorne VM (1989) Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes. N Engl J Med 321: 1074-1079
106. Pirart J (1978) Diabetes mellitus and its degenerative complications:a prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1: 168-188
107. Feldt-Rasmussen B, Deckert T (1993) Is metabolic control a determinant of renal disease progression in type I diabetic nephropathy. J Nephrology 2: 58-62
108. Hanssen KF, Dahl-Jørgensen K, Lauritzen T, Feldt-Rasmussen B, Brinchmann-Hansen O, Deckert T (1986) Diabetic control and microvascular complications. Diabetologia 29: 677-684
109. Mogensen CE (1986) Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy. Scand J Clin Lab Invest 46: 201-206
110. Rudberg S, Persson B, Dahlquist G (1992) Increased glomerular filtration rate as a predictor of diabetic nephropathy - an 8-year prospective study. Kidney Int 41: 822-828
111. Lervang H-H, Jensen S, Bröchner-Mortensen J, Ditzel J (1988) Early glomerular hyperfiltration and the development of late nephropathy in Type 1 (insulin-dependent) diabetes mellitus. Diabetologia 31: 723-729
112. Jones SL, Wiseman MJ, Viberti GC (1991) Glomerular hyperfiltration as a risk factor for diabetic nephropathy:five year report of a prospective study. Diabetologia 34:59-60
113. Rossing P, Borch-Johnsen K, Parving H-H (1993) Risk factors for development of incipient and overt diabetic nephropathy in IDDM patients. J Am Soc Nephrol 4: 308(Abstract)
114. Luetscher JA, Kramer FB, Wilson DM, Schwartz HC, Bryer-Ash M (1985) Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 312: 1412-1417
115. Wilson DM, Luetscher JA (1990) Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N Engl J Med 323: 1101-1106
116. Danser AHJ, van den Dorpel MA, Deinum J et al. (1989) Renin, prorenin, and immunoreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab 68: 160-167
117. Franken AAM, Derkx FHM, Man in't Veld AJ et al. (1990) High plasma prorenin in diabetes mellitus and its correlation with some complications. J Clin Endocrinol Metab 71: 1008-1015
118. Frimondt-Møller C (1978) Diabetic cystopathy. Dan Med Bull 25: 49-60
119. Telmer S, Christiansen JS, Andersen AR, Nerup J, Deckert T (1984) Smoking habits and prevalence of clinical diabetic microangiopathy in insulin-dependent diabetics. Acta Med Scand 215: 63-68
120. Nordén G, Nyberg G (1984) Smoking and diabetic nephropathy. Acta Med Scand 215: 257-261
121. Mühlhauser I, Sawicki PT, Berger M (1986) Cigarette smoking as a risk factor for macroproteinuria and proliferative retinopathy in Type 1 (insulin-dependent) diabetes. Diabetologia 29: 500-502
122. Chase HP, Garg SK, Marshall G et al. (1991) Cigarette smoking increases the risk of albuminuria among subjects with type 1 diabetes. JAMA 265: 614-617
123. Ravid M, Neumann L, Lishner M (1995) Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 47: 907-910
124. Østerby R, Gall M-A, Schmitz A, Nielsen FS, Nyberg G, Parving H-H (1993) Glomerular structure and function in proteinuric Type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 1064-1070
125. The Euclid Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792
126. Wang PH, Lau J, Chalmers TC (1993) Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 341: 1306-1309
127. Deckert T, Lauritzen T, Parving H-H, Christiansen JS. Steno Study Group (1983) Effect of two years of strict metabolic control on kidney function in long-term insulin-dependent diabetics. Diabetic Nephropathy 2: 6-10
128. The Kroc Collaborative Study Group. (1984) Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 311: 365-372
129. Beck-Nielsen H, Richelsen B, Mogensen CE et al. (1985) Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care 8: 585-589
130. Feldt-Rasmussen B, Mathiesen ER, Deckert T (1986) Effect of two years of strict metabolic control on progression of incipient nephropathy in insulin-dependent diabetes. Lancet ii:1300-1304
131. Christensen CK, Christiansen JS, Schmitz A, Christensen T, Hermansen K, Mogensen CE (1987) Effect of continous subcutaneous insulin infusion on kidney function and size in IDDM patients:a 2 year controlled study. J Diabetes Complications 1: 91-95
132. Dahl-Jørgensen K, Haussen KF, Kierulf P, Bjøro T, Sandvik L, Agenaes Ø (1988) Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin infusion in insulin-dependent diabetes mellitus. Acta Endocrinol 117: 19-25
133. Reichard P, Berglund B, Briz A, Cars I, Nilsson BY, Rosenqvist U (1991) Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM):the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 230: 101-108
134. The Diabetes Control and Complications Trial Research Group. (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 47: 1703-1720
135. Ohkubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospective 6-year study. Diabetes Research and Clinical Practice 28:103-117
136. The Microalbluminuria Captopril Study Group (1996) Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 39: 587-593
137. Ravid M, Lang R, Rachmani R, Lishner M (1996) Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. Arch Intern Med 156: 286-289
138. Sano T, Kawamura T, Matsumae H et al. (1994) Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 7: 420-424
139. Ahmad J, Siddiqui MA, Ahmad H (1997) Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20: 1576-1581
140. Marre M, Leblanc H, Suarez L, Guyenne T-T, Ménard J, Passa P (1987) Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. BMJ 294: 1448-1452
141. Marre M, Chatellier G, Leblanc H, Guyenne T-T, Ménard J, Passa P (1988) Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 297: 1092-1095
142. Laffel LMB, McGill JB, Gans JD (1995) The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99: 497-504
143. Viberti GC, Mogensen CE, Group L, Pauls JF, the European Microalbuminuria Captopril Study Group (1994) Effect of Captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 271: 275-279
144. Mathiesen ER, Hommel E, Giese J, Parving H-H (1991) Efficacy of captopril in postponing nephropathy in normotensive diabetic patients with microalbuminuria. BMJ 303: 81-87
145. Mathiesen ER, Hommel E, Hansen HP, Parving H-H (1997) Preservation of normal GFR with long term captopril treatment in normotensive IDDM patients with microalbuminuria. J Am Soc Nephrol 8: 115A(Abstract)
146. Reichard P, Nilsson BY, Rosenqvist U (1993) The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329: 304-309
147. Microalbuminuria Collaborative Study Group U (1995) Intensive therapy and progressive to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 311: 973-977
148. Bangstad H-J, Østerby R, Dahl-Jørgensen K, Berg K, Hartmann A, Hanssen KF (1994) Improvement of blood glucose control in IDDM patients retards the progression of morphological changes in early diabetic nephropathy. Diabetologia 37: 483-490
149. Mogensen CE, Keane WF, Bennett PH et al. (1995) Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346: 1080-1084
150. Borch-Johnsen K, Wenzel H, Viberti GC, Mogensen CE (1993) Is screening and intervention for microalbuminuria worthwhile in patients with insulin dependent diabetes. BMJ 306: 1722-1725
151. Hansen KW, Mau Pedersen M, Marshall SM, Christiansen JS, Mogensen CE (1992) Circadian variation of blood pressure in patients with diabetic nephropathy. Diabetologia 35: 1074-1079
152. Nielsen FS, Rossing P, Bang LE et al. (1995) On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy. Diabetes 44: 783-789
153. Karlefors T (1966) Circulatory studies during exercise with particular reference to diabetics. Acta Med Scand 180 [suppl 449]:1-87
154. Parving H-H, Kastrup J, Smidt UM, Andersen AR, Feldt-Rasmussen B, Christiansen JS (1984) Impaired autoregulation of glomerular filtration rate in Type 1 (insulin-dependent) diabetic patients with nephropathy. Diabetologia 27: 547-552
155. Christensen PK, Hansen HP, Parving H-H (1997) Impaired autoregulation of GFR in hypertensive non-insulin dependent diabetic patients. Kidney Int 52: 1369-1374
156. Rossing P, Hommel E, Smidt UM, Parving H-H (1994) Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37: 511-516
157. Rossing P, Hommel E, Smidt UM, Parving H-H (1994) Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45 [suppl. 45]: S145-S149
158. Breyer JA, Bain R, Evans JK et al. (1996) Predictors of the progression of renal insufficiency in patients with insulin-dependent diabetes and overt diabetic nephropathy. Kidney Int 50: 1651-1658
159. Mulec H, Johnsen SA, Carlström J, Björck S (1997) Initial decrease in proteinuria after institution of ACE inhibitor treatment predicts long term prognosis for kidney function in overt diabetic nephropathy. J Am Soc Nephrol 8: 116A(Abstract)
160. Apperloo AJ, de Zeeuw D, de Jong PE (1994) Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 45 [suppl. 45]:S174-S178
161. Peterson JC, Adler S, Burkart JM et al. (1995) Blood pressure control, proteinuria, and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med 123: 754-762
162. Jacobsen P, Rossing K, Rossing P et al. (1998) Role of an insertion/deletion polymorphism in the angiotensin converting enzyme gene on antiproteinuric effect of ACE inhibition in IDDM patients with diabetic nephropathy:an observational follow-up study. Kidney Int 53: 1002-1006
163. Tomonaga O, Ujihara N, Yokoyama H, Babazono T, Takahashi C, Iwamoto Y (1997) Angiotensin converting enzyme (ACE) gene polymorphism predicts the effect of ACE inhibitor (ACEI) on the progression of nephropathy in Japanese NIDDM patients. J Am Soc Nephrol 8: 120A(Abstract)
164. Rossing P, Hougaard P, Borch-Johnsen K, Parving H-H (1996) Predictors of mortality in insulin dependent diabetes: 10 year follow-up study. BMJ 313: 779-784
165. Hansen HP, Nielsen FS, Rossing P, Jacobsen P, Jensen BR, Parving H-H (1997) Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 52: S49-S53
166. Hansen HP, Rossing P, Tarnow L, Nielsen FS, Jensen BR, Parving H-H (1995) Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 47: 1726-1731
167. Apperloo AJ, de Zeeuw D, de Jong PE (1997) A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51: 793-797
168. Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 294: 1443-1447
169. Parving H-H, Smidt UM, Hommel E et al. (1993) Effective Antihypertensive Treatment Postpones Renal Insufficiency in Diabetic Nephropathy. Am J Kidney Dis 22: 188-195
170. Hommel E, Parving H-H, Mathiesen ER, Edsberg B, Nielsen MD, Giese J (1986) Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. BMJ 293: 466-470
171. Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M (1986) Beneficial effect of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 293: 471-474
172. Parving H-H, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 297: 1086-1091
173. Parving H-H, Hommel E, Nielsen MD, Giese J (1989) Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. BMJ 299: 533-536
174. Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M (1992) Renal protective effect of enalapril in diabetic nephropathy. BMJ 304: 339-343
175. Lewis E, Hunsicker L, Bain R, Rhode R (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329: 1456-1462
176. Krämer BK, Ritz E (1994) Is inhibition of the angiotensin-converting enzyme the treatment of choice in diabetic nephropathy? J Nephrol 7: 268-270
177. Bauer JH (1995) Are angiotensin-converting enzyme inhibitors the renal protective antihypertensive drugs of choice? Current Opinion in Nephrology and Hypertension 4: 427-431
178. Hommel E, Jensen B, Parving H-H (1995) Long term effect of captopril on kidney function in normotensive insulin dependent diabetic patients (IDDM) with diabetic nephropathy. J Am Soc Nephrol 6: 450(Abstract)
179. Walker WG, Hermann J, Anderson J, Zachary J, Russell RP (1992) Blood pressure (BP) control slows decline of glomerular filtration rate (GFR) in hypertensive NIDDM patients. J Am Soc Nephrol 3 (3):339(Abstract)
180. Lebovitz HE, Wiegmann TB, Cnaan A et al. (1994) Renal protective effects
181. Bakris GL, Copley JB, Vicknair N, Sadler R, Leugans S (1996) Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50: 1641-1650
182. Nielsen FS, Rossing P, Gall M-A, Skøtt P, Smidt UM, Parving H-H (1997) Long term effect of lisinopril and atenolol on kidney function in hypertensive non-insulin-dependent diabetic subjects with diabetic nephropathy. Diabetes 46: 1182-1188
183. Fioretto P, Mauer SM, Bilous RW, Goetz FC, Sutherland DER, Steffes MW (1993) Effects of pancreas transplantation of glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 342: 1193-1196
184. Viberti GC, Bilous RW, Mackintosh D, Bending JJ, Keen H (1983) Long term correction of hyperglycaemia and progression of renal failure in insulin dependent diabetes. BMJ 286: 598-602
185. Abouna GM, Kremer GD, Daddah SK, Al-Adnani MS, Kumar SA, Kusma G (1983) Reversal of diabetic nephropathy in human cadaveric kidneys after transplantation into non-diabetic recipients. Lancet ii:1274-1276
186. Fioretto P, Steffes MW, Sutherland DER, Goetz FC, Mauer SM (1997) Successful pancreas transplantation (PT) alone reverses established lesions of diabetic nephropathy (DN) in man. J Am Soc Nephrol 8: 111A(Abstract)
187. Parving H-H, Hommel E (1989) Prognosis in diabetic nephropathy. BMJ 299: 230-233
188. Mathiesen ER, Borch-Johnsen K, Jensen DV, Deckert T (1989) Improved survival in patients with diabetic nephropathy. Diabetologia 32: 884-886
189. Parving H-H, Jacobsen P, Rossing K, Smidt UM, Hommel E, Rossing P (1996) Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney Int 49: 1778-1782
190. Rodby RA, Firth LM, Lewis E, The Collaborative Study Group (1996) An economic analysis of captopril in the treatment of diabetic nephropathy. Diabetes Care 19: 1051-1061
191. Parving H-H (1996) Initiation and progression of diabetic nephropathy. N Engl J Med 335: 1682-1683